Atezolizumab/Cabozantinib Fails to Elicit Benefit Over SOC in Second-line Metastatic NSCLC
OncLive,
Enriqueta Felip, MD, PhD Second-line treatment with the combination of atezolizumab (Tecentriq) plus cabozantinib (Cabometyx…
Enriqueta Felip, MD, PhD Second-line treatment with the combination of atezolizumab (Tecentriq) plus cabozantinib (Cabometyx…
Nintedanib plus docetaxel offers significant efficacy in patients with non-small-cell lung cancer who experience disease…
Nintedanib plus docetaxel offers significant efficacy in patients with non-small-cell lung cancer who experience disease…